Jasper Therapeutics Inc Financials

JSPRW

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Jasper Therapeutics Inc (JSPRW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Jasper Therapeutics Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Jasper Therapeutics Inc generates $0.88 in operating cash flow (-$62.6M OCF vs -$71.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$74.9M

YoY-10.5%

Jasper Therapeutics Inc's EBITDA was -$74.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.5% from the prior year.

Free Cash Flow

N/A

Net Income

-$71.3M

YoY-10.6%

Jasper Therapeutics Inc reported -$71.3M in net income in fiscal year 2024. This represents a decrease of 10.6% from the prior year.

EPS (Diluted)

$-4.89

YoY+20.9%

Jasper Therapeutics Inc earned $-4.89 per diluted share (EPS) in fiscal year 2024. This represents an increase of 20.9% from the prior year.

Cash & Debt

$71.6M

YoY-17.6%

Jasper Therapeutics Inc held $71.6M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

15M

YoY+34.6%

Jasper Therapeutics Inc had 15M shares outstanding in fiscal year 2024. This represents an increase of 34.6% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$55.8M

YoY+7.8%

Jasper Therapeutics Inc invested $55.8M in research and development in fiscal year 2024. This represents an increase of 7.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

JSPRW Income Statement

Metric	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$55.8M+7.8%	$51.8M+49.6%	$34.6M+36.2%	$25.4M+60.1%	$15.9M
SG&A Expenses	$20.4M+19.6%	$17.1M+3.1%	$16.6M+45.2%	$11.4M+137.8%	$4.8M
Operating Income	-$76.2M-10.7%	-$68.9M-34.5%	-$51.2M-39.0%	-$36.8M-78.1%	-$20.7M
Interest Expense	N/A	-$246K-113.9%	-$115K-43.8%	-$80K+27.9%	-$111K
Income Tax	$2K0.0%	$2K	N/A	N/A	$38K
Net Income	-$71.3M-10.6%	-$64.5M-71.1%	-$37.7M-23.0%	-$30.6M+3.3%	-$31.7M
EPS (Diluted)	$-4.89+20.9%	$-6.18+40.2%	$-10.33	$-2.69	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$9.3M	N/A	N/A	$8.8M	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$14.4M-32.1%	$21.2M+31.2%	$16.2M+11.8%	$14.5M+28.0%	$11.3M+9.7%	$10.3M	N/A	$14.8M
SG&A Expenses	$4.8M-18.8%	$5.9M+4.2%	$5.6M+3.9%	$5.4M+15.7%	$4.7M-1.6%	$4.8M	N/A	$4.5M
Operating Income	-$19.2M+29.2%	-$27.1M-24.2%	-$21.8M-9.6%	-$19.9M-24.4%	-$16.0M-6.1%	-$15.1M	N/A	-$19.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$51K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$18.7M+29.9%	-$26.7M-25.8%	-$21.2M-14.0%	-$18.6M-27.8%	-$14.6M-6.2%	-$13.7M	N/A	-$17.5M
EPS (Diluted)	$-1.13+35.1%	$-1.74-23.4%	$-1.41-13.7%	$-1.24-27.8%	$-0.97+5.8%	$-1.03	N/A	$-1.60

JSPRW Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20
Total Assets	$79.9M-15.8%	$94.9M+96.2%	$48.4M-48.4%	$93.7M+301.0%	$23.4M
Current Assets	$75.8M-14.8%	$88.9M+113.1%	$41.7M-52.5%	$87.8M+324.6%	$20.7M
Cash & Equivalents	$71.6M-17.6%	$86.9M+127.2%	$38.3M-54.8%	$84.7M+327.0%	$19.8M
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$18.2M+10.8%	$16.5M+33.0%	$12.4M-48.7%	$24.1M-58.7%	$58.5M
Current Liabilities	$15.2M+23.1%	$12.4M+75.1%	$7.1M-11.9%	$8.0M+99.9%	$4.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A
Total Equity	$61.7M-21.4%	$78.4M+118.0%	$36.0M-48.2%	$69.5M+297.9%	-$35.1M
Retained Earnings	-$240.9M-42.0%	-$169.6M-61.3%	-$105.1M-55.9%	-$67.5M-83.2%	-$36.8M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$57.5M+23.7%	$46.5M-19.3%	$57.6M-27.9%	$79.9M-29.9%	$113.9M-9.6%	$126.0M+32.7%	$94.9M-14.1%	$110.4M
Current Assets	$54.6M+27.0%	$43.0M-19.2%	$53.2M-29.9%	$75.8M-30.2%	$108.7M-9.7%	$120.3M+35.3%	$88.9M-15.5%	$105.2M
Cash & Equivalents	$50.9M+28.8%	$39.5M-19.0%	$48.8M-31.9%	$71.6M-32.9%	$106.8M-9.8%	$118.5M+36.4%	$86.9M-16.3%	$103.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$45.9M+99.9%	$23.0M+49.6%	$15.4M-15.8%	$18.2M+33.8%	$13.6M+7.0%	$12.7M-22.6%	$16.5M+1.1%	$16.3M
Current Liabilities	$21.0M+2.6%	$20.5M+66.2%	$12.3M-19.1%	$15.2M+51.3%	$10.1M+12.9%	$8.9M-27.9%	$12.4M+3.9%	$11.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$11.6M-50.8%	$23.5M-44.4%	$42.2M-31.5%	$61.7M-38.5%	$100.3M-11.4%	$113.2M+44.4%	$78.4M-16.7%	$94.1M
Retained Earnings	-$307.6M-6.5%	-$288.8M-10.2%	-$262.1M-8.8%	-$240.9M-21.7%	-$197.9M-8.0%	-$183.3M-8.1%	-$169.6M-10.8%	-$153.0M

JSPRW Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$62.6M-20.2%	-$52.1M-13.5%	-$45.9M-36.2%	-$33.7M-84.4%	-$18.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$532K-99.3%	-$267K+53.6%	-$576K+76.3%	-$2.4M-1324.1%	$198K
Financing Cash Flow	$47.9M-52.6%	$101.0M+183483.6%	$55K-99.9%	$101.0M+794.6%	$11.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$17.0M-10.0%	-$15.5M+32.3%	-$22.8M-8.1%	-$21.1M-80.9%	-$11.7M+25.8%	-$15.7M+4.5%	-$16.5M-37.5%	-$12.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0-100.0%	$1K-75.0%	$4K+105.3%	-$76K+51.6%	-$157K-528.0%	-$25K+89.1%	-$230K	$0
Financing Cash Flow	$28.4M	N/A	N/A	$345K+90.6%	$181K-99.6%	$47.3M+17572.0%	-$271K-852.8%	$36K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

JSPRW Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A
Return on Assets	-89.2%-21.3pp	-67.9%+10.0pp	-77.9%-45.2pp	-32.7%+102.9pp	-135.6%
Current Ratio	4.98-2.2	7.19+1.3	5.91-5.0	10.95+5.8	5.16
Debt-to-Equity	0.30+0.1	0.21-0.1	0.340.0	0.35+2.0	-1.66
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-32.6%+24.9pp	-57.5%-20.6pp	-36.9%-18.1pp	-18.8%-5.9pp	-12.8%-1.9pp	-10.9%	N/A	-15.9%
Current Ratio	2.59+0.5	2.10-2.2	4.31-0.7	4.98-5.8	10.79-2.7	13.49+6.3	7.19-1.6	8.84
Debt-to-Equity	3.97+3.0	0.98+0.6	0.36+0.1	0.30+0.2	0.14+0.0	0.11-0.1	0.21+0.0	0.17
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Jasper Therapeutics Inc profitable?

No, Jasper Therapeutics Inc (JSPRW) reported a net income of -$71.3M in fiscal year 2024.

What is Jasper Therapeutics Inc's earnings per share (EPS)?

Jasper Therapeutics Inc (JSPRW) reported diluted earnings per share of $-4.89 for fiscal year 2024. This represents a 20.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Jasper Therapeutics Inc's EBITDA?

Jasper Therapeutics Inc (JSPRW) had EBITDA of -$74.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Jasper Therapeutics Inc's operating cash flow?

Jasper Therapeutics Inc (JSPRW) generated -$62.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Jasper Therapeutics Inc's total assets?

Jasper Therapeutics Inc (JSPRW) had $79.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Jasper Therapeutics Inc spend on research and development?

Jasper Therapeutics Inc (JSPRW) invested $55.8M in research and development during fiscal year 2024.

How many shares does Jasper Therapeutics Inc have outstanding?

Jasper Therapeutics Inc (JSPRW) had 15M shares outstanding as of fiscal year 2024.

What is Jasper Therapeutics Inc's current ratio?

Jasper Therapeutics Inc (JSPRW) had a current ratio of 4.98 as of fiscal year 2024, which is generally considered healthy.

What is Jasper Therapeutics Inc's debt-to-equity ratio?

Jasper Therapeutics Inc (JSPRW) had a debt-to-equity ratio of 0.30 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jasper Therapeutics Inc's return on assets (ROA)?

Jasper Therapeutics Inc (JSPRW) had a return on assets of -89.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Jasper Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Jasper Therapeutics Inc (JSPRW) had $71.6M in cash against an annual operating cash burn of $62.6M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Jasper Therapeutics Inc's Piotroski F-Score?

Jasper Therapeutics Inc (JSPRW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jasper Therapeutics Inc's earnings high quality?

Jasper Therapeutics Inc (JSPRW) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.